Tag: Precision oncology 2024

Home / Precision oncology 2024

Categories

Erdafitinib is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic uro...
precision-oncology-2024

Scan the code